In order to address a potential association of treatment response to HSP90 inhibitors with TP53 and PTPN11 mutations in primary AML and to confirm the response markers CD34, CD117, and CD11b, preclinical studies in larger cohorts are required. The gene discussed is KIT; the disease is acute myeloid leukemia.